LIXTE Receives U.S. Patent Issue Notification for Immune Oncology
September 04, 2024 08:30 ET
|
Lixte Biotechnology Holdings, Inc.
Patent Covers Combining LIXTE’s LB-100 with Various Innovative Cancer Immunotherapies PASADENA, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and...
LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI
February 26, 2024 08:30 ET
|
Lixte Biotechnology Holdings, Inc.
Agreement Focuses on Combining LIXTE’s LB-100 with Various Innovative Cancer Immunotherapies PASADENA, CA, Feb. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and...